$0.36
Live
0.28%
Downside
Day's Volatility :4.27%
Upside
4.0%
13.89%
Downside
52 Weeks Volatility :90.86%
Upside
89.38%
Period | Bionexus Gene Lab Corp | Index (Russel 2000) |
---|---|---|
3 Months | -25.1% | 0.0% |
6 Months | -40.15% | 0.0% |
1 Year | -17.55% | 0.0% |
3 Years | -98.48% | -23.0% |
Market Capitalization | 6.8M |
Book Value | $0.54 |
Earnings Per Share (EPS) | -0.15 |
Profit Margin | -24.01% |
Operating Margin TTM | 13.13% |
Return On Assets TTM | -10.11% |
Return On Equity TTM | -28.44% |
Revenue TTM | 9.2M |
Revenue Per Share TTM | 0.53 |
Quarterly Revenue Growth YOY | -23.1% |
Gross Profit TTM | 2.2M |
EBITDA | -1.5M |
Diluted Eps TTM | -0.15 |
Quarterly Earnings Growth YOY | -0.95 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 212.3K | - |
Net Income | 26.5K | - |
Net Profit Margin | 12.46% | - |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 127.0K | ↓ 40.21% |
Net Income | -246.5K | ↓ 1031.69% |
Net Profit Margin | -194.14% | ↓ 206.6% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 11.4M | ↑ 8872.03% |
Net Income | 1.1M | ↓ 543.91% |
Net Profit Margin | 9.61% | ↑ 203.75% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 13.4M | ↑ 17.31% |
Net Income | 751.6K | ↓ 31.31% |
Net Profit Margin | 5.62% | ↓ 3.99% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 10.9M | ↓ 18.21% |
Net Income | -356.0K | ↓ 147.36% |
Net Profit Margin | -3.26% | ↓ 8.88% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 9.8M | ↓ 10.6% |
Net Income | -2.6M | ↑ 638.57% |
Net Profit Margin | -26.91% | ↓ 23.65% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.4M | ↓ 16.28% |
Net Income | -69.1K | ↓ 56.0% |
Net Profit Margin | -2.91% | ↑ 2.62% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.6M | ↑ 7.98% |
Net Income | -259.3K | ↑ 275.37% |
Net Profit Margin | -10.1% | ↓ 7.19% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.6M | ↓ 0.51% |
Net Income | -2.6M | ↑ 906.03% |
Net Profit Margin | -102.13% | ↓ 92.03% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.3M | ↓ 10.99% |
Net Income | 307.4K | ↓ 111.79% |
Net Profit Margin | 13.52% | ↑ 115.65% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 2.4M | ↑ 4.79% |
Net Income | -103.8K | ↓ 133.75% |
Net Profit Margin | -4.36% | ↓ 17.88% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 2.0M | ↓ 17.1% |
Net Income | 199.1K | ↓ 291.89% |
Net Profit Margin | 10.08% | ↑ 14.44% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 1.7M | - |
Total Liabilities | 130.3K | - |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 1.2M | ↓ 25.48% |
Total Liabilities | 108.9K | ↓ 16.45% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 10.1M | ↑ 721.56% |
Total Liabilities | 3.5M | ↑ 3071.74% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 9.6M | ↓ 5.35% |
Total Liabilities | 2.4M | ↓ 30.65% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 8.7M | ↓ 8.71% |
Total Liabilities | 2.1M | ↓ 13.34% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 11.4M | ↑ 30.43% |
Total Liabilities | 1.7M | ↓ 16.06% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 8.2M | ↓ 6.33% |
Total Liabilities | 1.6M | ↓ 21.46% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 7.9M | ↓ 3.51% |
Total Liabilities | 1.9M | ↑ 18.74% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 11.5M | ↑ 45.15% |
Total Liabilities | 1.8M | ↓ 8.13% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 11.4M | ↓ 0.57% |
Total Liabilities | 1.7M | ↓ 2.02% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 11.2M | ↓ 2.09% |
Total Liabilities | 1.8M | ↑ 4.33% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 11.1M | ↓ 0.19% |
Total Liabilities | 1.6M | ↓ 12.29% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -274.1K | ↓ 176.73% |
Investing Cash Flow | -51.7K | ↓ 99.03% |
Financing Cash Flow | 742.9K | ↓ 87.15% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -217.3K | ↓ 20.73% |
Investing Cash Flow | -12.8K | ↓ 75.21% |
Financing Cash Flow | -180.8K | ↓ 124.34% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 552.7K | ↓ 354.37% |
Investing Cash Flow | 1.3M | ↓ 10398.74% |
Financing Cash Flow | -4.9K | ↓ 97.26% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 9.2K | ↓ 98.34% |
Investing Cash Flow | -490.6K | ↓ 137.16% |
Financing Cash Flow | -28.2K | ↑ 470.49% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -118.3K | ↓ 124.93% |
Investing Cash Flow | -5.1K | ↑ 65.34% |
Financing Cash Flow | -8.7K | ↓ 7243433.33% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -22.0K | ↓ 81.37% |
Investing Cash Flow | -3.1K | ↓ 39.52% |
Financing Cash Flow | -4.2K | ↓ 51.54% |
Sell
Neutral
Buy
Bionexus Gene Lab Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Bionexus Gene Lab Corp | -10.66% | -40.15% | -17.55% | -98.48% | -98.48% |
Air Products & Chemicals Inc. | 13.71% | 41.71% | 20.91% | 13.0% | 55.55% |
Linde Plc | 1.9% | 8.83% | 33.12% | 56.26% | 149.5% |
Dupont De Nemours Inc | 1.17% | 15.13% | 17.72% | 17.79% | 29.04% |
Sherwin-williams Company, The | 1.7% | 25.58% | 62.74% | 26.59% | 111.67% |
Ecolab Inc. | 2.59% | 19.22% | 64.29% | 17.62% | 36.45% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Bionexus Gene Lab Corp | NA | NA | NA | 0.0 | -0.28 | -0.1 | NA | 0.54 |
Air Products & Chemicals Inc. | 28.85 | 28.85 | 1.75 | 12.33 | 0.16 | 0.05 | 0.02 | 67.93 |
Linde Plc | 37.05 | 37.05 | 2.67 | 15.52 | 0.16 | 0.07 | 0.01 | 79.96 |
Dupont De Nemours Inc | 109.28 | 109.28 | 0.48 | 3.77 | 0.01 | 0.03 | 0.02 | 55.9 |
Sherwin-williams Company, The | 39.61 | 39.61 | 4.32 | 11.5 | 0.68 | 0.1 | 0.01 | 14.95 |
Ecolab Inc. | 43.21 | 43.21 | 2.52 | 6.63 | 0.22 | 0.07 | 0.01 | 23.46 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Bionexus Gene Lab Corp | NA | $6.8M | -98.48% | NA | -24.01% |
Air Products & Chemicals Inc. | Buy | $73.8B | 55.55% | 28.85 | 21.24% |
Linde Plc | Buy | $232.1B | 149.5% | 37.05 | 19.49% |
Dupont De Nemours Inc | Buy | $35.6B | 29.04% | 109.28 | 5.51% |
Sherwin-williams Company, The | Buy | $98.2B | 111.67% | 39.61 | 10.92% |
Ecolab Inc. | Hold | $73.2B | 36.45% | 43.21 | 10.95% |
Insights on Bionexus Gene Lab Corp
Revenue is down for the last 2 quarters, 2.38M → 1.97M (in $), with an average decrease of 17.1% per quarter
Netprofit is up for the last 2 quarters, -103.75K → 199.10K (in $), with an average increase of 152.1% per quarter
In the last 1 year, Ecolab Inc. has given 63.5% return, outperforming this stock by 75.2%
Organization | Bionexus Gene Lab Corp |
Employees | 30 |
CEO | Mr. Su-Leng Tan |
Industry | Commercial Services |
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$0.36
-2.96%
Invesco Bulletshares 2025 Hi
$0.36
-2.96%
Schwab International Dividend Equity Etf
$0.36
-2.96%
Blockchain Coinvestors Acquisition Corp.
$0.36
-2.96%
Allgiant Travel Company
$0.36
-2.96%
Rogers Corp
$0.36
-2.96%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$0.36
-2.96%
Iheartmedia
$0.36
-2.96%
Lightpath Technologies Inc
$0.36
-2.96%